TY  - GEN
AU  - Fazio,Nicola
AU  - Buzzoni,Roberto
AU  - Baudin,Eric
AU  - Antonuzzo,Lorenzo
AU  - Hubner,Richard A
AU  - Lahner,Harald
AU  - DE Herder,Wouter W
AU  - Raderer,Markus
AU  - Teulé,Alexandre
AU  - Capdevila,Jaume
AU  - Libutti,Steven K
AU  - Kulke,Matthew H
AU  - Shah,Manisha
AU  - Dey,Debarshi
AU  - Turri,Sabine
AU  - Aimone,Paola
AU  - Massacesi,Cristian
AU  - Verslype,Chris
TI  - A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours
SN  - 1791-7530
PY  - 2016///0712
KW  - Administration, Oral
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Agents
KW  - administration & dosage
KW  - Drug Administration Schedule
KW  - Drug Resistance, Neoplasm
KW  - Everolimus
KW  - therapeutic use
KW  - Female
KW  - Humans
KW  - Imidazoles
KW  - Male
KW  - Middle Aged
KW  - Neuroendocrine Tumors
KW  - drug therapy
KW  - Pancreatic Neoplasms
KW  - Phosphatidylinositol 3-Kinase
KW  - metabolism
KW  - Phosphoinositide-3 Kinase Inhibitors
KW  - Prospective Studies
KW  - Protein Kinase Inhibitors
KW  - Quinolines
KW  - TOR Serine-Threonine Kinases
KW  - antagonists & inhibitors
KW  - Time Factors
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
ER  -